These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9025110)

  • 1. Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity.
    Hatanaka K; Nomura T; Hidaka K; Takeuchi H; Yatsugi S; Fujii M; Yamaguchi T
    Neuropharmacology; 1996; 35(11):1621-6. PubMed ID: 9025110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity.
    Takeuchi H; Yatsugi S; Hatanaka K; Nakato K; Hattori H; Sonoda R; Koshiya K; Fujii M; Yamaguchi T
    Eur J Pharmacol; 1997 Jun; 329(1):27-35. PubMed ID: 9218680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons.
    Szabo ST; Blier P
    J Pharmacol Exp Ther; 2002 Sep; 302(3):983-91. PubMed ID: 12183655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of acute treatment with YM992 on extracellular serotonin levels in the rat frontal cortex.
    Hatanaka K; Yatsugi S; Yamaguchi T
    Eur J Pharmacol; 2000 Apr; 395(1):23-9. PubMed ID: 10781669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model.
    Takeuchi H; Yatsugi S; Yamaguchi T
    Jpn J Pharmacol; 2002 Oct; 90(2):197-200. PubMed ID: 12419892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the serotonin reuptake blocking property of YM992: electrophysiological studies in the rat hippocampus and dorsal raphe.
    Dong J; De Montigny C; Blier P
    Synapse; 1999 Dec; 34(4):277-89. PubMed ID: 10529722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex.
    Hatanaka K; Yatsugi S; Yamaguchi T
    Eur J Pharmacol; 2000 Apr; 395(1):31-6. PubMed ID: 10781670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.
    Matzen L; van Amsterdam C; Rautenberg W; Greiner HE; Harting J; Seyfried CA; Böttcher H
    J Med Chem; 2000 Mar; 43(6):1149-57. PubMed ID: 10737747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors.
    Tordera RM; Monge A; Del Río J; Lasheras B
    Eur J Pharmacol; 2002 May; 442(1-2):63-71. PubMed ID: 12020683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Consequences of the monoaminergic systems cross-talk in the antidepressant activity].
    Tritschler L; Gaillard R; Gardier AM; David DJ; Guilloux JP
    Encephale; 2018 Jun; 44(3):264-273. PubMed ID: 29801770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
    Sánchez C; Hyttel J
    Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.
    Gobert A; Millan MJ
    Neuropsychopharmacology; 1999 Aug; 21(2):268-84. PubMed ID: 10432475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats.
    Gobert A; Rivet JM; Cistarelli L; Melon C; Millan MJ
    J Neurochem; 1997 Dec; 69(6):2616-9. PubMed ID: 9375697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue.
    Scott C; Soffin EM; Hill M; Atkinson PJ; Langmead CJ; Wren PB; Faedo S; Gordon LJ; Price GW; Bromidge S; Johnson CN; Hagan JJ; Watson J
    Eur J Pharmacol; 2006 Apr; 536(1-2):54-61. PubMed ID: 16571351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors.
    McMahon LR; Cunningham KA
    Neuropsychopharmacology; 2001 Mar; 24(3):319-29. PubMed ID: 11166521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological effects of milnacipran, a new antidepressant, given repeatedly on the alpha1-adrenergic and serotonergic 5-HT2A systems.
    Maj J; Rogóz Z; Dlaboga D; Dziedzicka-Wasylewska M
    J Neural Transm (Vienna); 2000; 107(11):1345-59. PubMed ID: 11145008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Developments on Future Antidepressant-related Serotonin Receptors.
    Amidfar M; Kim YK
    Curr Pharm Des; 2018; 24(22):2541-2548. PubMed ID: 30073919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
    Martínez-Esparza J; Oficialdegui AM; Pérez-Silanes S; Heras B; Orús L; Palop JA; Lasheras B; Roca J; Mourelle M; Bosch A; Del Castillo JC; Tordera R; Del Río J; Monge A
    J Med Chem; 2001 Feb; 44(3):418-28. PubMed ID: 11462981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.